### Estimated Costs to the Federal Government

The maximum cost to the Federal Government is $750,000 annually for FY 2007, FY 2008, and FY 2009. Most of the work will be carried out through contracts. The costs were estimated at $200 for each face-to-face interview, $100 for each telephone interview, $5,000 for each focus group, $10,000 for Web-based surveys, and $20,000 for each laboratory testing module. Any deviation from these limits will be noted in reports made to OMB with respect to a particular study or studies conducted under the clearance.

### Request for Comments

In accordance with the above-cited legislation, comments on AHRQ’s information collection are requested with regard to any of the following:

- Whether the proposed collection of information is necessary for the proper performance of health care information dissemination functions of AHRQ, including whether the information will have practical utility;
- The accuracy of AHRQ’s estimate of burden (including hours and costs) of the proposed collection(s) of information;
- Ways to enhance the quality, utility, and clarity of the information to be collected; and
- Ways to minimize the burden of the collection of information upon the respondents, including the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and included in the request for OMB approval of the proposed information collection. All comments will become a matter of public record.


Carolyn M. Clancy,
Director.

[FR Doc. 06–7585 Filed 9–11–06; 8:45 am]

### DEPARTMENT OF HEALTH AND HUMAN SERVICES

#### Food and Drug Administration

[Docket No. 2006D–0344]

**Draft Guidance for Industry on Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling; Availability**

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled “Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling.” This document is intended to provide recommendations to sponsors of new drug applications (NDAs), and biologic license applications (BLAs) for therapeutic biologics (drugs) on carrying out in vitro or in vivo drug-drug interaction studies. The draft guidance reflects the current view that the metabolism and transport of a new drug should be defined during drug development and that its interactions with other drugs should be explored as part of an adequate assessment of the safety and effectiveness of the drug.

**DATES:** Submit written or electronic comments on the draft guidance by November 13, 2006. General comments on agency guidance documents are welcome at any time.

**ADDRESSES:** Submit written requests for single copies of this draft guidance to the Division of Drug Information (HFD–240), Center for Drug Evaluation and Research, Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857; or the Office of Communication, Training, and Manufacturers Assistance (HFM–40), Center for Biologics Evaluation and Research (CBER), 1401 Rockville Pike, Rockville, MD 20852–1448. Send one self-addressed adhesive label to assist that office in processing your requests.

Submit written comments on the draft guidance to the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. Submit electronic comments to http://www.fda.gov/dockets/ecomments. See the SUPPLEMENTARY INFORMATION section for electronic access to the draft guidance document.

**FOR FURTHER INFORMATION CONTACT:** Shiew-Mei Huang, Center for Drug Evaluation and Research (HFD–850), Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 21, rm. 4550, Silver Spring, MD 20993–0002, 301–796–1541, or Toni Stifano, Center for Biologics Evaluation and Research (HFM–600), Food and Drug Administration, 1401 Rockville Pike, Rockville, MD 20852, 301–827–6190.

**SUPPLEMENTARY INFORMATION:**

### I. Background

FDA is announcing the availability of a draft guidance for industry entitled “Drug Interaction Studies—Study Design, Data Analysis, and Implications for Dosing and Labeling.” FDA previously published two guidance documents on the use of in vitro and in vivo approaches to study metabolism and metabolic drug-drug interactions entitled “Drug Metabolism/Drug Interaction Studies in the Drug Development Process: Studies in Vitro” and “In Vivo Drug Metabolism/Drug Interaction Studies—Study Design, Data Analysis, and Recommendations for Dosing and Labeling.” The draft guidance, when finalized, will replace these guidance documents. This draft guidance discusses study design, choice of interacting drugs, data analysis, and provides recommendations for dosing and labeling.

This draft guidance is being issued consistent with FDA’s good guidance practices regulation (21 CFR 10.115). The draft guidance, when finalized, will represent the agency’s current thinking.
DEPARTMENT OF HOMELAND SECURITY

Notice

Advisory Committee to the Office of State and Local Training

AGENCY: Federal Law Enforcement Training Center (FLETC), DHS.

ACTION: Notice of Federal Advisory Committee Meeting.

SUMMARY: The Advisory Committee to the Office of State and Local Training (OSL) will meet on October 4, 2006, in Brunswick, GA. The meeting will be open to the public.

DATES: The Advisory Committee to the Office of State and Local Training will meet Wednesday, October 4, 2006, from 8 a.m. to 3 p.m. Please note that the meeting may close early if the committee has completed its business.

ADDRESS: The meeting will be held at the Holiday Inn Express, 138 Glynco Parkway, Brunswick, GA. Send written material, comments, and/or requests to make an oral presentation to Reba Fischer, Designated Federal Officer (DFO), 1131 Chapel Crossing Road (TH 396), Glycno, GA 31524. Written materials, comments, and/or requests to make an oral presentation at the meeting should reach the contact person listed below by September 22, 2006. Requests to have a copy of your material distributed to each member of the committee prior to the meeting should reach the contact person at the address below by September 22, 2006. Comments must be identified by FLET C–2006–0003 and may be submitted by one of the following methods:

- E-mail: reba.fischer@dhs.gov. Include docket number in the subject line of the message.
- Fax: (912) 267–3531. (Not a toll-free number).
- Mail: Reba Fischer, Federal Law Enforcement Training Center, Department of Homeland Security, 1131 Chapel Crossing Road, Townhouse 396, Glycno, GA 31524.

Instructions: All submissions received must include the words “Department of Homeland Security” and the docket number for this action. Comments received will be posted without alteration at www.regulations.gov, including any personal information provided.

Docket: For access to the docket to read background documents or comments received by the Advisory Committee to the Office of State and Local Training, go to www.regulations.gov.

FOR FURTHER INFORMATION CONTACT: Reba Fischer, Designated Federal Officer, 912–267–2343, reba.fischer@dhs.gov.

SUPPLEMENTARY INFORMATION: Notice of this meeting is given under the Federal Advisory Committee Act, 5 U.S.C. App. 1 et seg. (Pub. L. 92–463). The mission of the Advisory Committee to the Office of State and Local Training is to advise and make recommendations on matters relating to the selection, development, content and delivery of training services by the OSL/FLET C to its State, local, campus, and tribal law enforcement customers.

Draft Agenda

The draft agenda for this meeting includes briefings and discussion on training; new initiatives; training validation; strategic goals; and the training needs of State, local, campus, and tribal law enforcement officers.

Procedural

This meeting is open to the public. Please note that the meeting may close early if all business is finished.

At the discretion of the Co-chairs, members of the public may make an oral presentation during the meeting. If you would like to make an oral presentation at the meeting, please notify Reba Fischer. If you would like a copy of your material distributed to each member of the Committee in advance of the meeting, please submit 25 copies to Reba Fischer by September 22, 2006.

Visitors must pre-register attendance to ensure adequate seating. Please provide your name and telephone number by close of business on September 22, 2006, to Reba Fischer (contact information above).

Information on Services for Individuals With Disabilities

For information on facilities or services for individuals with disabilities or to request special assistance at the meeting, contact Reba Fischer (contact information above) as soon as possible.

Dated: September 1, 2006.

Seymour Jones,
Deputy Assistant Director, Office of State and Local Law Enforcement Training.

[F R Doc. E6–15075 Filed 9–11–06; 8:45 am]
BILLING CODE 4810–32–P

DEPARTMENT OF HOMELAND SECURITY

Office of the Secretary

[Docket Number DHS–2006–0047]

Privacy Act; Systems of Records


ACTION: Notice of Privacy Act system of records.

SUMMARY: Pursuant to the Privacy Act of 1974, the Department of Homeland Security, Office of Security, proposes to add a new system of records to the Department’s inventory, entitled the “Personal Identity Verification Management System.” This system will support the administration of the HSPD–12 program that directs the use of a common identification credential for both logical and physical access to federally controlled facilities and information systems. This system will enhance security, increase efficiency, reduce identify fraud, and protect personal privacy.

DATES: The established system of records will be effective October 12,